Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
The DBV Technologies S.A. (DBVT) news page on Stock Titan aggregates company announcements, regulatory disclosures, and clinical development updates for this clinical-stage biopharmaceutical issuer. DBV Technologies focuses on food allergies and other immunologic conditions with significant unmet medical need, using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) platform.
Investors and followers of DBV Technologies can use this news feed to review company-issued press releases and market announcements. Recent communications from DBV Technologies have covered topics such as progress in its Viaskin Peanut clinical program in peanut-allergic toddlers and children, including the Phase 3 VITESSE trial in children aged 4 to 7 years. The company has reported that VITESSE met its primary endpoint and that safety results were consistent with the existing Viaskin Peanut clinical program, positioning this trial as a key milestone in its development strategy.
In addition to clinical data updates, DBV Technologies news items include information on supplemental safety studies in toddlers, participation in healthcare and investor conferences, and changes in leadership and board composition. The company also releases regulated information related to its Euronext Paris listing, such as monthly disclosures of total shares and voting rights and reports on its liquidity contract.
Regulatory filings summarized in press releases, including U.S. SEC Form 8-K reports, provide insight into financial results, equity financing arrangements, and other corporate events. By following DBV Technologies news, readers can track developments in the Viaskin platform, food allergy programs, and the company’s dual listing on Euronext Paris and the Nasdaq Capital Market.
DBV Technologies has announced major leadership changes effective October 2, 2020. CFO Ramzi Benamar and CCO Kevin Trapp will depart, while Sébastien Robitaille will assume the CFO role. Robitaille, with a tenure at DBV since 2015, brings extensive experience through various leadership positions, including Chief Transformation Officer. The company expresses gratitude for the outgoing executives' contributions, highlighting Benamar's role in strengthening the balance sheet and Trapp's development of a commercial strategy for Viaskin Peanut. DBV also noted a recent FDA Complete Response Letter regarding its Biologics License Application.
DBV Technologies, a clinical-stage biopharmaceutical company, announced participation in several investor conferences in September 2020, including:
- Citi’s 15th Annual BioPharma Virtual Conference on September 9-10.
- Goldman Sachs 10th Annual Biotech Symposium on September 11.
- H. C. Wainwright 22nd Annual Global Investment Conference from September 14-16, featuring a fireside chat by CEO Daniel Tassé on September 15 at 10:00 AM ET.
- Morgan Stanley 18th Annual Global Healthcare Conference from September 14-18, with Daniel Tassé speaking on September 16 at 8:45 AM ET.
Webcasts of these events will be available on DBV's website.
As of July 31, 2020, the company reports a total of 54,927,187 shares outstanding. The total number of voting rights amounts to 54,927,187 gross and 54,867,787 net, after excluding shares without voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers for market transparency.